ICU sedation, delirium & recovery
Efficacy and safety of oliceridine versus remifentanil for analgesia in mechanically ventilated critically ill adults (CO-ROAM): a multicenter, assessor-blinded, non-inferiority randomized controlled trial
Primary result · Time in target analgesic range (TTR)Result — go to the resultAbsolute difference 3.7% 95% CI −0.3 to 5.7%Authors' conclusion
Oliceridine provides non-inferior analgesia to remifentanil with a more favourable respiratory safety profile and lower costs in critically ill adults.
Study context
- Population
- Adults receiving invasive mechanical ventilation (IMV) in 19 intensive care units (ICUs) in Chinamodified intention-to-treat population, of 307 randomised patients
- Participants
- 304 adults
- Comparison
- Oliceridine or remifentanil, titrated to a Critical-Care Pain Observation Tool score below 3
- Oliceridinen = 151
- Remifentaniln = 153reference
- Primary endpoint
- Time in target analgesic range (TTR)
Methodological detailsmodified intention-to-treat population
- Modified intention-to-treat population
Primary result
Time in target analgesic range (TTR)
Oliceridinevs remifentanil
absolute difference 3.7% (95% CI −0.3 to 5.7%)
As reported in the abstract
Further findings
Analgesic-sedation costs
- Lower with oliceridine
IMV duration, ICU stay, and 28-day mortality
- Did not differ
Subgroup analyses (subgroup)
- Nominal ADR benefit in patients with Acute Physiology and Chronic Health Evaluation II > 17
- Larger nominal TTR difference in those without acute respiratory distress syndrome
Safety
Events per 100 patient-days
| Outcome | Oliceridine | Remifentanil | IRR (95% CI) | P value | |
|---|---|---|---|---|---|
| Mild-to-moderate adverse drug reactions (ADRs) | 15.9 | 22.2 | 0.72 (0.52–1.00) | P = 0.049 | |
| 0.512Incidence rate ratio (log scale) |
Respiratory depression during the study period · lower with oliceridine
P = 0.015
Post-extubation respiratory depression · lower with oliceridine
P = 0.005
Original publication
Efficacy and safety of oliceridine versus remifentanil for analgesia in mechanically ventilated critically ill adults (CO-ROAM): a multicenter, assessor-blinded, non-inferiority randomized controlled trial. Intensive Care Med. Published 10 November 2026. doi:10. 1007/ s00134-026-08643-8
Composed by AI from the published abstract and checked against it. How Briefs are made →